产品
编 号：F748679
分子式：C23H24N4O4S
分子量：452.53
分子式：C23H24N4O4S
分子量：452.53
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
结构图
CAS No: 2073059-82-0
产品详情
生物活性：
SBI-993 is a SBI-477 analog with improved potency and suitable pharmacokinetic properties for in vivo bioavailability. SBI-993 stimulates insulin signaling by deactivating the transcription factor MondoA.
体内研究：
SBI-993 (50 mg/kg; s.c.; daily; for 7 days) treatment reduces the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver. SBI-993 also reduces Txnip and Arrdc4 expression. And ccupation of both ChREBP and MondoA on the Txnip and pyruvate kinase (Pklr) gene promoters is reduced in liver by SBI-993.SBI-993 improves insulin signaling in both muscle and liver following an acute insulin challenge.Animal Model:Mice are fed a 60% high-fat diet (HFD)
Dosage:50 mg/kg
Administration:s.c.; daily; for 7 days
Result:Reduced the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver.
体外研究：
SBI-993 reduces thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4) expression in human myotubes.
SBI-993 is a SBI-477 analog with improved potency and suitable pharmacokinetic properties for in vivo bioavailability. SBI-993 stimulates insulin signaling by deactivating the transcription factor MondoA.
体内研究：
SBI-993 (50 mg/kg; s.c.; daily; for 7 days) treatment reduces the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver. SBI-993 also reduces Txnip and Arrdc4 expression. And ccupation of both ChREBP and MondoA on the Txnip and pyruvate kinase (Pklr) gene promoters is reduced in liver by SBI-993.SBI-993 improves insulin signaling in both muscle and liver following an acute insulin challenge.Animal Model:Mice are fed a 60% high-fat diet (HFD)
Dosage:50 mg/kg
Administration:s.c.; daily; for 7 days
Result:Reduced the expression of triacylglyceride synthesis and lipogenic genes in both muscle and liver.
体外研究：
SBI-993 reduces thioredoxin-interacting protein (TXNIP) and arrestin domain-containing 4 (ARRDC4) expression in human myotubes.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备